121 related articles for article (PubMed ID: 22818892)
1. Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Waldron NN; Oh S; Vallera DA
Oral Oncol; 2012 Dec; 48(12):1202-7. PubMed ID: 22818892
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.
Albo D; Tuszynski GP
J Surg Res; 2004 Jul; 120(1):21-6. PubMed ID: 15172186
[TBL] [Abstract][Full Text] [Related]
3. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Christensen A; Juhl K; Persson M; Charabi BW; Mortensen J; Kiss K; Lelkaitis G; Rubek N; von Buchwald C; Kjær A
Oncotarget; 2017 Feb; 8(9):15407-15419. PubMed ID: 28039488
[TBL] [Abstract][Full Text] [Related]
4. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.
Oh F; Modiano JF; Bachanova V; Vallera DA
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32630411
[TBL] [Abstract][Full Text] [Related]
6. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
7. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
Niu G; Li Z; Xie J; Le QT; Chen X
J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
9. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.
Stegeman H; Kaanders JH; Wheeler DL; van der Kogel AJ; Verheijen MM; Waaijer SJ; Iida M; Grénman R; Span PN; Bussink J
BMC Cancer; 2012 Oct; 12():463. PubMed ID: 23046567
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
12. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.
Knowles JA; Heath CH; Saini R; Umphrey H; Warram J; Hoyt K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2012 Jul; 138(7):662-8. PubMed ID: 22801891
[TBL] [Abstract][Full Text] [Related]
14. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
15. Bioactive phytochemical proanthocyanidins inhibit growth of head and neck squamous cell carcinoma cells by targeting multiple signaling molecules.
Prasad R; Katiyar SK
PLoS One; 2012; 7(9):e46404. PubMed ID: 23050025
[TBL] [Abstract][Full Text] [Related]
16. EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models.
Qiu Y; Qi Z; Wang Z; Cao Y; Lu L; Zhang H; Mathes D; Pomfret EA; Lu SL; Wang Z
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36579667
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
[TBL] [Abstract][Full Text] [Related]
18. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.
Abhold EL; Kiang A; Rahimy E; Kuo SZ; Wang-Rodriguez J; Lopez JP; Blair KJ; Yu MA; Haas M; Brumund KT; Altuna X; Patel A; Weisman RA; Ongkeko WM
PLoS One; 2012; 7(2):e32459. PubMed ID: 22384257
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in South Asian head and neck squamous cell carcinoma: association with various risk factors and clinico-pathologic and prognostic parameters.
Hashmi AA; Hussain ZF; Aijaz S; Irfan M; Khan EY; Naz S; Faridi N; Khan A; Edhi MM
World J Surg Oncol; 2018 Jun; 16(1):118. PubMed ID: 29954411
[TBL] [Abstract][Full Text] [Related]
20. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
